Could the Next Generation of GLP-1 Medications Be Even More Effective? Meet EloraTZP

Just when you thought GLP-1 medications couldn't get any more interesting, Eli Lilly announced results from a clinical trial that caught my attention.

The company behind Zepbound and Mounjaro is studying a new combination treatment that pairs tirzepatide with an investigational medication called eloralintide.

The combination is called EloraTZP, and the early results are impressive.

How impressive? Participants receiving the highest-dose combination lost an average of 23.3% of their body weight over 48 weeks, compared with 14.8% for participants receiving tirzepatide alone.

That's a pretty significant difference.

But before we get too excited, let's talk about what this medication actually is, how it works, and what the study tells us.

First, What Is Eloralintide?

Most of us in the GLP-1 community are familiar with medications like Zepbound, Mounjaro, Wegovy and Ozempic.

These medications work by targeting hormones involved in appetite, blood sugar regulation and digestion.

Tirzepatide, the active ingredient in Zepbound and Mounjaro, targets two hormone receptors:

GLP-1: Helps regulate appetite, blood sugar and digestion.

GIP: Works alongside GLP-1 to influence insulin secretion and metabolic regulation.

Eloralintide takes a different approach.

It's an investigational medication designed to mimic the effects of amylin, a hormone naturally released by the pancreas alongside insulin.

Amylin helps regulate appetite and promotes feelings of fullness after eating.

By combining eloralintide with tirzepatide, researchers are targeting three different hormonal pathways: GLP-1, GIP and amylin.

The theory is that targeting multiple pathways could produce greater weight loss and improvements in blood sugar than targeting GLP-1 and GIP alone.

What Did the Clinical Trial Find?

On September 30, 2026, Eli Lilly announced results from a 48-week Phase 2b clinical trial involving 367 adults with obesity or overweight and type 2 diabetes.

Researchers compared several doses of the combination treatment against tirzepatide alone, eloralintide alone and placebo.

Here's where things get interesting.

Average Weight Loss After 48 Weeks

The combination group lost approximately 20 more pounds on average than the group taking tirzepatide alone.

That's a substantial difference over approximately 11 months.

Participants also experienced improvements in A1C, a measure of average blood sugar over approximately three months.

The highest-dose combination reduced A1C by an average of 2.9 percentage points, compared with 2.4 percentage points for tirzepatide alone.

These figures come from Lilly's reported efficacy analysis, which estimates outcomes had participants remained on their assigned treatment. Results varied by dose, and individual outcomes differed.

Does This Mean EloraTZP Is Better Than Zepbound?

Not necessarily.

The results suggest that combining tirzepatide with eloralintide may produce greater weight loss than tirzepatide alone.

However, there are some important considerations.

First, this was a Phase 2b study, meaning researchers were still evaluating dosing, effectiveness and safety.

Second, all participants had type 2 diabetes. We can't automatically assume the same results would occur in people taking GLP-1 medications for weight management without diabetes.

Third, and perhaps most importantly, the combination treatment produced more gastrointestinal side effects.

And if you've been on a GLP-1, you already know those are not exactly the side effects anyone is hoping to increase.

What About Side Effects?

Here's where the study gets particularly interesting.

The most common side effects were gastrointestinal, including issues such as nausea, vomiting and diarrhea.

These occurred more frequently in participants receiving the combination than in those receiving either medication alone.

Between 10.8% and 27% of participants receiving EloraTZP discontinued treatment because of adverse events, depending on the dose combination.

For comparison, approximately 2.9% of participants taking tirzepatide alone discontinued because of adverse events.

That's a meaningful difference.

Lilly reported that gastrointestinal side effects were generally mild or moderate and occurred primarily during dose increases.

The company plans to study a modified dose-escalation schedule in Phase 3 trials, potentially improving tolerability. Whether that approach succeeds remains to be seen.

Will This Be Another Weekly Injection?

In the Phase 2b trial, participants received tirzepatide and eloralintide as separate injections.

However, Eli Lilly plans to develop a combined formulation for future Phase 3 trials.

The goal is to bring the two medications together rather than requiring patients to administer separate injections.

Eloralintide itself is being studied as a once-weekly medication.

The final dosing schedule and delivery system for EloraTZP will depend on additional clinical research and regulatory review.

When Could EloraTZP Become Available?

Not anytime immediately.

Although the Phase 2b results are encouraging, EloraTZP is still an investigational treatment.

Lilly has announced plans to begin Phase 3 trials in the fourth quarter of 2026.

These larger studies will help researchers better understand the medication's effectiveness, side effects and long-term safety.

If those studies are successful, the company would still need to seek regulatory approval before the medication could become commercially available.

As of October 2026, EloraTZP is not FDA-approved and is not available as a prescribed treatment.

And importantly, patients should not attempt to combine investigational eloralintide with their existing tirzepatide treatment outside a properly supervised clinical trial.

Why This Research Matters to the GLP-1 Community

Having been on a GLP-1 journey myself, I find developments like this fascinating.

Not because everyone needs to lose more weight or because newer automatically means better.

But because we're beginning to understand just how many different hormonal pathways influence appetite, weight and metabolic health.

And researchers are looking beyond GLP-1 alone.

For some people, existing medications provide excellent results.

Others experience frustrating plateaus, struggle with side effects or don't achieve the weight loss they hoped for.

Future combination therapies may eventually provide additional treatment options.

But the real question isn't simply how much weight someone can lose.

It's whether a medication can help people achieve meaningful, sustainable health improvements with side effects they can reasonably tolerate.

That's what I'll be watching as this research progresses.

The Bottom Line

Eli Lilly's EloraTZP is one of the more interesting developments in the next generation of weight-management medications.

Combining tirzepatide with an amylin-based treatment produced greater average weight loss than tirzepatide alone in a Phase 2b trial involving adults with type 2 diabetes.

But the combination also caused more side effects and higher treatment discontinuation rates.

The results are promising, but we're not at the finish line yet.

I'll be following the Phase 3 research closely.

Because if there's one thing I've learned throughout my GLP-1 journey, it's that the science keeps evolving.

And that's pretty exciting.

Supporting Your GLP-1 Journey Today

While researchers continue developing the next generation of medications, everyday challenges like hydration, protein intake, digestion and self-care aren't going anywhere.

That's why I created My Companion Box, a discovery box designed specifically for people navigating life on GLP-1 medications.

Each box introduces products to try before committing to full-size purchases.

Try more. Waste less. Find what works for you.

→ Discover the Latest My Companion Box

Medical disclaimer: This article is for educational purposes only and is not medical advice. EloraTZP and eloralintide are investigational medications. Consult your healthcare provider about treatment options and never change or combine prescription medications without medical supervision.

These are worth including at the bottom of the published article so readers can explore the actual research.

Primary source: Eli Lilly's September 30, 2026 Phase 2b Trial Results

Clinical trial: ClinicalTrials.gov Study NCT06603571

Background: Eli Lilly: What to Know About Eloralintide